Company intelligence / Profile preview

LG

Seoul, South Korea

Ownership: Private
Employees: ~20000
Development stage: Other

Overview

LG Chem has successfully commercialized multiple drugs and vaccines, achieved the first US FDA approval for a Korean NCE (Factive), launched innovative diabetes and growth hormone therapies, and most recently entered the U.S. oncology market by acquiring AVEO; additionally, it has licensed novel obesity therapeutics and advanced several programs to global markets[1][2].

Therapeutic areas: OncologyInfectious DiseasesEndocrinology
Modalities: Small moleculeBiologicMonoclonal antibodyVaccineBiosimilar
Industry: Biotech

Partnerships

Rhythm Pharmaceuticals (US; obesity drug out-licensing)Multiple academic and industry collaborations

Beyond the preview

Go deeper on LG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on LG.

Explore the full profile